Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways
Authors
Keywords
-
Journal
Oncogenesis
Volume 3, Issue 5, Pages e102-e102
Publisher
Springer Nature
Online
2014-05-12
DOI
10.1038/oncsis.2014.16
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Galloflavin suppresses lactate dehydrogenase activity and causes MYC downregulation in Burkitt lymphoma cells through NAD/NADH-dependent inhibition of sirtuin-1
- (2013) Marina Vettraino et al. ANTI-CANCER DRUGS
- Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds
- (2013) Carlotta Granchi et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
- (2012) Tongyuan Li et al. CELL
- AMPK: a nutrient and energy sensor that maintains energy homeostasis
- (2012) D. Grahame Hardie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- p53 Negatively Regulates Transcription of the Pyruvate Dehydrogenase Kinase Pdk2
- (2011) T. Contractor et al. CANCER RESEARCH
- Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth
- (2011) J. Chen et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- JNK2-dependent regulation of SIRT1 protein stability
- (2011) Jack Ford et al. CELL CYCLE
- Galloflavin (CAS 568-80-9): A Novel Inhibitor of Lactate Dehydrogenase
- (2011) Marcella Manerba et al. ChemMedChem
- SIRT1, metabolism and cancer
- (2011) John R.P. Knight et al. CURRENT OPINION IN ONCOLOGY
- SIRT1 RNAi knockdown induces apoptosis and senescence, inhibits invasion and enhances chemosensitivity in pancreatic cancer cells
- (2011) G Zhao et al. GENE THERAPY
- Discovery ofN-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform A (LDH-A) as Starvation Agents against Cancer Cells
- (2011) Carlotta Granchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sacrifice for survival
- (2011) Nana-Maria Grüning et al. NATURE
- SIRT1 Undergoes Alternative Splicing in a Novel Auto-Regulatory Loop with p53
- (2010) Cian J. Lynch et al. PLoS One
- Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
- (2010) A. Le et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data
- (2009) Anne von Heideman et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Enzymes in the NAD+Salvage Pathway Regulate SIRT1 Activity at Target Gene Promoters
- (2009) Tong Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer
- (2009) H. Xie et al. MOLECULAR CANCER THERAPEUTICS
- Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
- (2009) M. G. Vander Heiden et al. SCIENCE
- Acetylation Is Indispensable for p53 Activation
- (2008) Yi Tang et al. CELL
- Brick by brick: metabolism and tumor cell growth
- (2008) Ralph J DeBerardinis et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Molecular pathogenesis of bladder cancer
- (2008) Margaret A. Knowles International Journal of Clinical Oncology
- miR-34a repression of SIRT1 regulates apoptosis
- (2008) M. Yamakuchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started